[HTML][HTML] Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels
…, A Rosado, T Caniego-Casas, N Carrizo… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Background Tumor mutational burden (TMB) is a recently proposed predictive biomarker for
immunotherapy in solid tumors, including non-small cell lung cancer (NSCLC). Available …
immunotherapy in solid tumors, including non-small cell lung cancer (NSCLC). Available …
[HTML][HTML] Comprehensive characterization of human lung large cell carcinoma identifies transcriptomic signatures with potential implications in response to …
…, R García-Luján, J Zugazagoitia, N Carrizo… - Journal of Clinical …, 2022 - mdpi.com
Lung cancer is the leading cause of cancer mortality worldwide, with non-small cell lung
cancer (NSCLC) being the most prevalent histology. While immunotherapy with checkpoint …
cancer (NSCLC) being the most prevalent histology. While immunotherapy with checkpoint …
Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non–Small-Cell Lung Cancer Patients for Genotype …
J Zugazagoitia, D Rueda, N Carrizo, AB Enguita… - Clinical Lung Cancer, 2018 - Elsevier
Introduction A substantial fraction of non–small-cell lung cancers (NSCLCs) harbor targetable
genetic alterations. In this study, we analyzed the feasibility and clinical utility of integrating …
genetic alterations. In this study, we analyzed the feasibility and clinical utility of integrating …
PD-L1, VISTA, and CD47 expression and prognosis impact in malignant pleural mesothelioma.
M Herrera, AC Ucero, AB Enguita, N Carrizo, R Yarza… - 2022 - ascopubs.org
8562 Background: Malignant Pleural Mesothelioma (MPM) has been characterized by an
immune suppressive microenvironment. The immune checkpoint (IC) VISTA is notably …
immune suppressive microenvironment. The immune checkpoint (IC) VISTA is notably …
Identification of predictive biomarkers of immunotherapy response in non-small cell lung cancer by multiparametric analysis
…, D Gomez-Sanchez, A Rosado, I Ferrer, N Carrizo… - 2021 - Eur Respiratory Soc
Non-Small-Cell Lung Cancer (NSCLC) leads cancer incidence and mortality. Immune
checkpoint blockers showed promising results, yet responders cannot be accurately selected as …
checkpoint blockers showed promising results, yet responders cannot be accurately selected as …
Enabling biomarkers of chromosomal instability for tumor only targeted gene panel sequencing
…, M Escobar-Rey, R Moreno-Vellisca, N Carrizo… - Cancer Research, 2024 - AACR
Capture-based targeted sequencing is routinely used for small variant detection in cancer
clinical care. Alongside targeted DNA, off-target DNA is also sequenced. These off-target …
clinical care. Alongside targeted DNA, off-target DNA is also sequenced. These off-target …
[PDF][PDF] Comprehensive multiparametric analysis of non-small cell lung cancer describes novel genotype-immunophenotype relationships and provides putative …
…, A Rosado, I Ferrer, N Carrizo… - Cancer …, 2020 - media.sparx-ip.net
Presentación de PowerPoint Page 1 Comprehensive multiparametric analysis of Non-Small
Cell Lung Cancer describes novel genotype-immunophenotype relationships and provides …
Cell Lung Cancer describes novel genotype-immunophenotype relationships and provides …
Comprehensive analysis of non-small cell lung cancer identifies molecular genotype-immunophenotype associations and candidate biomarkers predictive of …
…, D Gomez-Sanchez, A Rosado, AC Ucero, N Carrizo… - Cancer Research, 2022 - AACR
Lung cancer has the second highest incidence and leads cancer mortality worldwide, being
Non-Small Cell Lung Cancer (NSCLC) the most prevalent subtype. Immunotherapy with …
Non-Small Cell Lung Cancer (NSCLC) the most prevalent subtype. Immunotherapy with …
Interleukin-11 could be a novel therapeutic target for lung adenocarcinoma patients
…, J Ramos-Paradas, P Yagüe, A Santos, N Carrizo… - Cancer Research, 2020 - AACR
Interleukin-11 (IL11) has been associated with tumorigenesis in a wide variety of tumors,
including lung cancer, and it has been proposed as a diagnostic biomarker for lung …
including lung cancer, and it has been proposed as a diagnostic biomarker for lung …
Evaluation of novel therapeutic strategies for KRAS mutated NSCLC patients using our own collections of PDX and PDX-derived organoids
…, D Gomez, AC Ucero, L Garcia, P Plaza, N Carrizo… - Cancer Research, 2022 - AACR
3101: Evaluation of novel therapeutic strategies for KRAS mutated NSCLC patients using
our own collections of PDX and PDX-derived organoids | Cancer Research | American …
our own collections of PDX and PDX-derived organoids | Cancer Research | American …